Arecoline improved glucose and lipid metabolism in type 2 diabetic rats

Chinese Pharmacological Bulletin

Volumn 25, Issue 11, 2009, Pages 1477-1481

  Yao, Qi Xin ^a   Qi, Zhu Qing ^a   Wang, Guang ^a   Zhang, Wei ^a   Zhou, Shou Hong ^a   Ling, Hong Yan ^a   Hu, Bi ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Arecoline; Diabetic animal; FoxO1; Glyconeogenesis; High fructose diet; Insulin resistance; PGC 1 ; Type 2 diabetes

Indexed keywords

ARECOLINE; CHOLESTEROL; FRUCTOSE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); TRANSCRIPTION FACTOR FKHR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77349116399     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Moller D E. New drug targets for type 2 diabetes and the metabolic syndrome[J]. Nature, 2001, 414 : 821-7.
2. Zhao H Z, Xiao J Z, Yang W Y, et al. Relationship between hepatic insulin resistance and the expression of genes involved hepatic glucoe output[J]. Chin J Hepatol, 2006, 14(1) : 45-8.
3. Zheng H Z, et al. Research and application of modern medicine [M]. Beijing : the Academe Press, 1999 : 4565.
4. He C H, Xia G J, Li G L, et al. Studies on synergic effect of arecoline in combination with snaik-killing drugs [J]. Chin J Schisto Control, 1999, 11(4) : 21.
5. Chen D M, Mu S F, Wang H. Antithrombosis through activating endothelial target for acetylcholine and its molecular mechanism [J]. Chin Pharmacol Bull, 2002, 18(5) : 527.
6. Shang L M, Zhang J C, Zhao Y L, et al. Molecular mechanisms for arecoline against atherosclerosis [J]. Chin Pharmacol Bull, 2004, 20(2) : 146-51.
7. Zhang W, Zhou S H, Ling H Y, et al. Arecoline repressed inflamma tion factor expression of macrophages stimulated by oxidzed low density lipoprote in and its mechanism[J]. Chin J Arterioscler, 2009, 17(4) : 269-72.
8. Reaven G M, Hwang I S, Ho H. Fructose induced insulin resistance and hypertension in rats[J]. Hypertension, 1987, 10 : 512-6.
9. Zhang L, Dai M, Chen L M, Xuan Z H, Establishment of a rat model with insulin-resistant fatty liver induced by high-fat and high-sucrose emulsion[J]. Chin Pharmacol Bull, 25(6) : 825-8.
10. Li G W, Pan X R, Stephen L. A new insulin-sensitivity index for the population-based study[J]. Chin J Intern Med, 1993, 32(10) : 656-60.
11. Goto M, Yoshioka T, Battelino T, et al. TNFalpha decreases gluconeogenesis in hepatocytes isolated from 10-day-old rats[J]. Pediatr Res, 2001, 49 : 552-7.
12. Li H T, Jia W P, Bao Y Q, Molecular mechanisms for Foxol and Foxa2 on hepatic insulin resistance[J]. Shanghai Med J, 2008, 31(11) : 825-7.
13. Kodama S, Moore R, Yamamoto Y, Negishi M. Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene[J]. Biochem J, 2007, 407 : 373-81.
14. Matsuzaki H, Daitoku H, Hatta M, et al. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation [J]. Proc Natl Acad Sci USA, 2003, 100 : 11285-90.
15. Ropelle E R, Pauli J R, Cintra D E, et al. Acute exercise modulates the Foxo1/PGC-1 alpha pathway in the liver of diet-induced obesity rats[J]. J Physiol, 2009, 587(Pt 9) : 2069-76.